Industry
Biotechnology
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Loading...
Open
13.93
Mkt cap
2B
Volume
819K
High
14.18
P/E Ratio
-12.00
52-wk high
16.74
Low
13.41
Div yield
N/A
52-wk low
3.50
Portfolio Pulse from
December 23, 2024 | 1:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 1:49 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 9:12 pm
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 1:51 pm
Portfolio Pulse from Lekha Gupta
October 20, 2024 | 9:22 pm
Portfolio Pulse from Benzinga Newsdesk
October 17, 2024 | 10:55 am
Portfolio Pulse from Avi Kapoor
October 16, 2024 | 6:43 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.